LEXX stock news · Lexaria Bioscience
Get alerts for LEXX
Follow Lexaria Bioscience (LEXX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LEXX12 health care stocks changed a lot in prices during Friday's after-hours trading.
NeutralLexaria Bioscience shares rose 10% in Friday's after-market session. The roundup gives no business news that changes its outlook.
12 health care stocks changed a lot in prices during Thursday's after-hours trading.
NeutralLexaria Bioscience shares rose 10.72% after hours. The article gives no company update or reason, so this move alone does not change its business outlook.
12 health care companies saw big changes in their stock prices after the market closed on Wednesday.
NeutralLexaria Bioscience shares fell 10.41% to $3.10 after hours, but the roundup gives no company news, so its business outlook is unchanged.
On Thursday evening, 12 health care stocks changed a lot in price, with Prime Medicine jumping 13%.
NeutralLexaria Bioscience shares fell 6.53% to $3.15 after-market; the piece only reports market moves and market cap, so it does not change the company's outlook.
On Thursday evening, 12 health care stocks changed a lot in price.
NeutralLexaria Bioscience shares rose 11.18% to $3.66 after hours, but the article provides no business or trial details, so it does not change the company's outlook.
Lexaria Bioscience Corp. signs an important agreement and will issue new warrants.
NeutralLexaria raised about $5.9M from warrant exercises while creating new warrants for 453,969 shares; cash improves liquidity but added dilution cancels, so outlook remains unchanged.
On Tuesday, 12 health care stocks saw big price changes during the day.
Bad for LEXXLexaria Bioscience fell 35.5% to $9.12 during the session, signaling heavy selling pressure that weakens sentiment.
Thursday saw a 29.41% surge in Lexaria Bioscience shares: Key insights for investors.
NeutralLexaria Bioscience shares surged 29.41% following the announcement of a new Material Transfer Agreement with PegBio, which will allow Lexaria to utilize its DehydraTECH technology to enhance the delivery of GLP-1 therapies. This partnership is seen as a strategic move to capitalize on the growing market for GLP-1 treatments, potentially increasing Lexaria's market presence and revenue…
Notice issued to Lexaria Bioscience Corp. regarding potential delisting for not adhering to ongoing listing criteria; listing transfer anticipated (LEXX).
Bad for LEXXLexaria Bioscience Corp. has filed a Form 8-K indicating that it has received a notice of delisting due to not meeting continued listing standards. This news is likely to lead to a decline in investor confidence and a bearish sentiment surrounding the stock, making it crucial for investors to act quickly.